Bayer Stock Forecast 2035: Bull, Bear, and Base Case

01. Historical Context

Bayer in context: what the current discount is actually pricing

At EUR 38.15 on May 15, 2026, Bayer is still a turnaround and litigation story, not a finished quality compounder. The share is down -43.8% from EUR 67.87 on May 31, 2016 and its monthly adjusted range over the last decade spans EUR 19.17 to EUR 89.06.

The latest operating data is better than the long chart suggests. Bayer reported FY2025 sales of EUR 46.6 billion, and in Q1 2026 sales rose to EUR 13.405 billion (+4.1% currency- and portfolio-adjusted), EBITDA before special items rose to EUR 4.453 billion (+9.0%), and core EPS improved to EUR 2.71 (+12.9%).

Even so, the stock is still being valued through the legal overhang. Reported FY2025 EPS was negative EUR 3.68, so a normal trailing P/E is not useful. Investors instead fall back on core EPS, where the stock trades around 8.3x on the latest full-year base and 8.3x to 9.3x forward.

Data-backed summary visual — Data-backed summary using current price, 10-year performance, latest quarterly results, and scenario ranges.

Bayer framework across investor time horizons

Horizon	What matters now	What would strengthen the thesis	What would weaken the thesis
Next 6 months	Guidance credibility, key events, and FX	Quarterly results keep beating the implied pace	Guidance slips or a major event turns negative
12-24 months	Launch quality, cash conversion, and balance-sheet pressure	New products outgrow legacy drag	Cash flow or divisional execution weakens
To 2035	Sustainable EPS compounding and the multiple investors will still pay	Execution proves durable enough to hold the valuation	Execution weakens and the market stops paying a premium

02. Key Forces

Five forces that matter most from here

A 2035 view on Bayer has to begin with humility. Over the last decade the share delivered a -43.8% total return, with a CAGR of -5.6%.

Second, the stock's starting valuation does create long-run optionality. At about 8.3x to 9.3x on current core EPS guidance, Bayer does not need a premium multiple to produce reasonable returns.

Third, the group structure matters. Crop Science, Pharmaceuticals and Consumer Health each have a plausible role in recovery, but the market will likely continue to judge Bayer at the group level until the glyphosate story is materially cleaner.

Fourth, long-run equity value depends on what happens after the heavy 2026 litigation cash outflow.

Fifth, AI and R&D modernization are interesting long-run positives, but Bayer signed a three-year strategic AI collaboration with Cradle on January 7, 2026 to improve antibody discovery, and its Annual Report 2025 also highlights AI-led chemistry work through AgPlenus in Crop Science.

Five-factor scoring lens for Bayer

Factor	Current assessment	Bias	What would improve it	What would weaken it
Operating momentum	Latest quarter revenue was EUR 13.405 billion after FY2025 revenue of EUR 46.6 billion.	Mixed to constructive	Another quarter of volume and mix-driven growth	A guidance cut or weaker divisional mix
Earnings quality	Latest quarter core EPS was EUR 2.71.	Mixed	Cash conversion and margin stability	One-off items start masking softer underlying demand
Balance sheet / cash flow	The market wants proof that earnings translate into clean cash.	Bearish on legal overhang	Lower leverage or better free cash flow	More cash drain, debt pressure, or legal outflows
Valuation	The stock trades around 8.3x on the latest core earnings base and 8.3x to 9.3x forward by current assumptions.	Cheap	EPS upgrades without another multiple jump	Any sign the market already paid for perfection
Catalyst path	The operating case improved in Q1 2026 because Crop Science EBITDA before special items rose 17.9% to EUR 3.014 billion, but Pharmaceuticals still has to prove that launch assets can offset loss-of-exclusivity pressure.	Event-driven	Clear approvals, launches, or legal de-risking	A regulatory setback or delayed decision

03. Countercase

What would break the thesis

Bayer's Annual Report 2025 says glyphosate provisions and liabilities totaled US$11.3 billion (EUR 9.6 billion) as of December 31, 2025, and management expects about EUR 5 billion of litigation payouts in 2026.

The second risk is that Q1 2026 may overstate operating momentum. Crop Science benefited from a soy licensing resolution and better seed performance, but Pharmaceuticals still has to deal with loss-of-exclusivity pressure. Q1 2026 free cash flow was minus EUR 2.320 billion.

Third, the share is cheap for a reason. A core multiple of only 8.3x looks attractive, but it is only cheap if the legal bill stops growing and if 2026 guidance actually translates into cleaner cash generation in 2027 and beyond.

Finally, macro matters through agriculture and rates. Bayer is more exposed than premium pharma peers to lower farmer sentiment, FX swings and a higher cost of capital.

Current downside checklist

Risk	Current data point	Why it matters now	Review trigger
Glyphosate litigation	Provision and liabilities were US$11.3 billion (EUR 9.6 billion) at December 31, 2025.	That overhang still dominates free cash flow and investor confidence.	Supreme Court ruling expected by end-June 2026 and any settlement updates.
Cash flow strain	Q1 2026 free cash flow was minus EUR 2.320 billion.	Strong EBITDA does not help equity holders much if cash leaves through litigation and restructuring.	Watch Q2 and full-year free cash flow versus guidance.
Pharma execution	Q1 Pharma sales were roughly in line year on year while segment earnings fell.	A rerating needs proof that new launches can offset older-product pressure.	Re-check after each quarterly divisional update.
Valuation trap risk	The stock looks cheap at 8.3x to 9.3x forward core EPS, but reported FY2025 EPS was negative EUR 3.68.	Cheap valuation does not help if legal and cash-flow risk remain unresolved.	The setup improves only if cash generation normalizes after legal payments.

04. Institutional Lens

What current institutional work adds to the analysis

The institutional lens for 2035 is mainly about sequencing. First comes the near-term legal and cash-flow repair. Only after that does long-run valuation become a normal exercise.

The company has given investors a usable earnings bridge: 2026 constant-currency core EPS of EUR 4.30 to EUR 4.80, with an FX-refreshed range of EUR 4.10 to EUR 4.60.

That is why a 2035 forecast should be wide. The range is not indecision; it is an honest reflection of how much still depends on legal, strategic and divisional execution over many years.

What current institutional and primary-source signals actually say about Bayer

Source	Latest update	What it said	Why it matters
Company results	May 12, 2026	Latest quarter delivered revenue of EUR 13.405 billion and core EPS of EUR 2.71.	This is the cleanest read on whether the base case is intact.
Annual results	March 4, 2026	FY2025 revenue was EUR 46.6 billion and the full-year earnings base was EUR 4.57 under the new 2026 methodology and EUR 4.91 under the old presentation core EPS with reported EPS of negative EUR 3.68.	It anchors valuation work and avoids projecting from a single quarter.
Company outlook	May 12, 2026	Bayer confirmed on May 12, 2026 that currency-adjusted 2026 guidance still calls for EUR 45 billion to EUR 47 billion of sales and EUR 4.30 to EUR 4.80 of core EPS, while the FX-refreshed range is EUR 44.5 billion to EUR 46.5 billion of sales and EUR 4.10 to EUR 4.60 of core EPS.	This is the clearest public bridge from current operations to 2026 earnings power.
Reuters legal	April 27, 2026	Reuters reported on April 27, 2026 that the U.S. Supreme Court appeared divided in Bayer's Roundup case and that a ruling is expected by the end of June 2026. Reuters also noted the outcome could influence the fate of more than 100,000 glyphosate-related claims.	This is the main public marker for the discount-rate shock that still dominates the stock.

05. Scenarios

Scenario analysis investors can actually use

Base case, probability 35%: Bayer reaches EUR 48 to EUR 70 by 2035. That assumes the legal overhang fades over time, normalized core EPS rises gradually, and the market keeps the stock on a modest but stable multiple.

Bull case, probability 35%: the stock reaches EUR 75 to EUR 100. This needs the legal discount to shrink sharply, free cash flow to turn cleanly positive after 2026, and investors to pay a better multiple for a repaired portfolio.

Bear case, probability 30%: the stock remains in EUR 23 to EUR 40. That would happen if litigation remains structurally expensive or if the underlying businesses fail to produce durable cash returns despite their scale.

2035 scenario map for Bayer

Scenario	Probability	Price range	Measurable trigger	Review date	Suggested posture
Bull	35%	EUR 75 to EUR 100	Legal overhang falls sharply and normalized free cash flow becomes reliable	Annual review after 2026	Own for rerating only if the balance sheet actually improves
Base	35%	EUR 48 to EUR 70	Slow repair with moderate EPS growth and limited multiple expansion	Every annual report	Patience is required; position sizes should reflect uncertainty
Bear	30%	EUR 23 to EUR 40	Legal drag and weak cash generation continue longer than expected	Any year with renewed large provisions	Do not confuse a low multiple with a margin of safety